Last reviewed · How we verify
SCE-B
SCE-B, marketed by Duramed Research, is a small molecule drug with a specific biological mechanism, positioned in the market with its key composition patent expiring in 2028. The drug's key strength lies in its targeted therapeutic effect, which differentiates it from broader-spectrum alternatives. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | SCE-B |
|---|---|
| Also known as | Synthetic Conjugated Estrogens, B, Enjuvia |
| Sponsor | Duramed Research |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Feasibility of a Comprehensive Behavioral Intervention in Patient Post TKA (PHASE1,PHASE2)
- Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCE-B CI brief — competitive landscape report
- SCE-B updates RSS · CI watch RSS
- Duramed Research portfolio CI